摘要
随着碳青霉烯类抗菌药物的广泛使用,耐碳青霉烯肺炎克雷伯菌(carbapenem resistant klebsiella pneumoniae,CRKP)已成为全球公共卫生的“紧急”优先事项。CRKP所致的感染与高死亡率相关,是医院感染的重要病原体。CRKP主要的耐药机制是碳青霉烯酶的产生,临床可用的有效抗菌药物有限,目前部分新型抗菌药物对CRKP有较高的活性及安全性。本文对CRKP的耐药机制、新型抗菌药物的应用进行评述,以供临床参考与借鉴。
With the widespread use of carbapenem antibiotics,carbapenem resistant Klebsiella pneumoniae(CRKP)has be⁃come an"urgent"global public health priority.CRKP infections are associated with high mortality and CRKP is an important pathogen of nosocomial infections.The main drug resistance mechanism of CRKP is the production of carbapenemase,and the effective antibiot⁃ics available in clinic are limited.At present,some new antibiotics show high activity and safety against CRKP.In this paper,the mecha⁃nism of drug resistance and new antimicrobial agents of CRKP were reviewed for clinical reference.
作者
袁喆
钱克莉
王忠杰
YUAN Zhe;QIAN Keli;WANG Zhongjie(Department of Infectious Diseases,The First Affiliated Hospital of Chongqing Medical University,Chongqing 400016,China;Department of Infection Control,The First Affiliated Hospital of Chongqing Medical University,Chongqing 400016,China)
出处
《西南医科大学学报》
2024年第2期104-110,共7页
Journal of Southwest Medical University
基金
重庆市自然科学基金(CSTC2009BB5061)
重庆人社局科研基金(09958013)。
关键词
肺炎克雷伯菌
碳青霉烯耐药
耐药机制
Klebsiella pneumoniae
Carbapenem resistance
Drug resistance mechanism
